Clinical Trials Browser

INDUSTRY × Recurrence × Bendamustine Hydrochloride × Clear all

NCT06522737 2026-02-11

TERZO

Phase 3 Recruiting

Immunoblastic Lymphadenopathy, Lymphoma, Recurrence, Lymphoma, T-Cell, Peripheral

NCT04607772 2025-10-03

Study of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL)

Phase 1/2 Withdrawn

Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT03039114 2025-08-21

Study Evaluating Safety and Efficacy of INCB050465 Combined With Bendamustine and Obinutuzumab in Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Phase 1 Completed

Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Recurrence

NCT01611090 2020-03-03

A Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Phase 3 Completed

578 enrolled 21 charts

LymphoidOther hematologic neoplasm

Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell

NCT01294579 2018-08-09

Ofatumumab and Bendamustine Followed by Maintenance Ofatumumab for Rituximab Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (B-NHL)

Phase 2 Completed

49 enrolled 13 charts

Lymphoma, Non-Hodgkin, Recurrence

NCT01466153 2017-05-31

A Phase 2, Multicenter, Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

Phase 2 Completed

183 enrolled 17 charts

LymphoidOther hematologic neoplasm

Leukemia, Lymphoma, Non-Hodgkin, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell

NCT01520922 2017-01-19

Ofatumumab Plus Bendamustine in Frontline and Relapsed Chronic Lymphocytic Leukaemia (CLL)

Phase 2 Completed

99 enrolled 27 charts

LymphoidOther hematologic neoplasm

Leukemia, Lymphoid, Neoplasms, Recurrence, Leukemia, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma